Holen Sie sich die Stockscreener-App
1.10
9.09%
-0.11
Schlusskurs vom Vortag:
$1.21
Offen:
$1.21
24-Stunden-Volumen:
601.93K
Relative Volume:
1.54
Marktkapitalisierung:
$62.25M
Einnahmen:
$21.05M
Nettoeinkommen (Verlust:
$-89.22M
KGV:
-0.6145
EPS:
-1.79
Netto-Cashflow:
$-64.50M
1W Leistung:
-18.52%
1M Leistung:
-45.54%
6M Leistung:
-80.04%
1J Leistung:
-84.49%
1-Tages-Spanne:
$1.09
$1.26
1-Wochen-Bereich:
$1.09
$1.46
52-Wochen-Spanne:
$1.09
$9.69
Tscan Therapeutics Inc Stock (TCRX) Company Profile
Firmenname
Tscan Therapeutics Inc
Sektor
Branche
Telefon
857-399-9500
Adresse
880 WINTER STREET, WALTHAM
Vergleichen Sie TCRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TCRX
Tscan Therapeutics Inc
|
1.10 | 62.25M | 21.05M | -89.22M | -64.50M | -1.79 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Tscan Therapeutics Inc Stock (TCRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-05-16 | Eingeleitet | BTIG Research | Buy |
| 2024-05-13 | Eingeleitet | Needham | Buy |
| 2023-06-22 | Eingeleitet | Wedbush | Outperform |
Tscan Therapeutics Inc Aktie (TCRX) Neueste Nachrichten
Monitoring Gentherm Inc (THRM) after recent insider movements - knoxdaily.com
TScan Therapeutics, Inc. (NASDAQ:TCRX) Short Interest Update - Defense World
TScan Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference - The Manila Times
Exclusive Look: TScan Reveals Latest Cancer Therapy Progress at Major Healthcare Conference - Stock Titan
Tscan Therapeutics Inc [TCRX] Shares Fall Approximately -81.72% Over the Year - Knox Daily
TScan Therapeutics Appoints Commercial Leader Stephen Camiolo as Senior Vice President, Market Access - Quantisnow
Cell Therapy Veteran With 16 Successful Launches Joins TScan Leadership - Stock Titan
Analysts Set TScan Therapeutics, Inc. (NASDAQ:TCRX) PT at $9.33 - Defense World
TScan Therapeutics (NASDAQ:TCRX) Earns Overweight Rating from Morgan Stanley - Defense World
Weekly Investment Analysts’ Ratings Changes for TScan Therapeutics (TCRX) - Defense World
TScan Therapeutics’ SWOT analysis: biotech stock navigates clinical milestones By Investing.com - Investing.com Australia
HC Wainwright Expects Weaker Earnings for TScan Therapeutics - MarketBeat
Positive Buy Rating for TScan Therapeutics Driven by Promising Clinical Data and Strong Financial Position - TipRanks
TScan Therapeutics’ SWOT analysis: biotech stock navigates clinical milestones - Investing.com India
Head to Head Analysis: TScan Therapeutics (NASDAQ:TCRX) versus Novavax (NASDAQ:NVAX) - Defense World
Analysts Set Expectations for TCRX FY2029 Earnings - MarketBeat
TScan Therapeutics Reports 2024 Financial Results and Progress - TipRanks
Q2 EPS Estimate for TScan Therapeutics Lowered by Analyst - Defense World
Wedbush Equities Analysts Cut Earnings Estimates for TCRX - Defense World
Research Analysts Set Expectations for TCRX FY2029 Earnings - Defense World
TScan Therapeutics’ (TCRX) Buy Rating Reiterated at HC Wainwright - Defense World
Barclays Issues Pessimistic Forecast for TScan Therapeutics (NASDAQ:TCRX) Stock Price - Defense World
TScan: 2 Major Milestones Of TSC-101 To Carry Tide In 2025 (NASDAQ:TCRX) - Seeking Alpha
HC Wainwright Reiterates "Buy" Rating for TScan Therapeutics (NASDAQ:TCRX) - MarketBeat
TScan Therapeutics price target lowered to $3 from $14 at Barclays - TipRanks
Needham & Company LLC Issues Pessimistic Forecast for TScan Therapeutics (NASDAQ:TCRX) Stock Price - Defense World
TScan Therapeutics (NASDAQ:TCRX) Earns Outperform Rating from Wedbush - Defense World
H.C. Wainwright maintains $15 target on Tscan shares By Investing.com - Investing.com Canada
TCR Therapy Clinical Trial Pipeline Accelerates as 80+ Pharma Companies Rigorously Developing Drugs for the Market Entry | DelveInsight - GlobeNewswire Inc.
H.C. Wainwright maintains $15 target on Tscan shares - Investing.com India
Breaking Down TScan Therapeutics: 4 Analysts Share Their Views - Benzinga
TScan Therapeutics Inc Files For Mixed Shelf Of Up To $300 Million -March 05, 2025 at 04:54 pm EST - Marketscreener.com
Tscan Therapeutics earnings missed, revenue fell short of estimates By Investing.com - Investing.com UK
TScan Therapeutics reports Q4 EPS (30c), consensus (28c) - TipRanks
TScan Therapeutics, Inc. (TCRX) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance
TScan Therapeutics, Inc. SEC 10-K Report - TradingView
TScan Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - The Manila Times
TScan Therapeutics (NASDAQ:TCRX) Stock Price Down 11.9% – Here’s What Happened - Defense World
TScan Therapeutics Announces Upcoming Presentation at the TD Cowen 45th Annual Health Care Conference - The Manila Times
How Will TScan's Cancer Therapy Pipeline Impress Investors at Major Healthcare Conference? - Stock Titan
TScan Therapeutics to Participate in the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference - GlobeNewswire
Inside TScan's Revolutionary TCR Cell Therapy Pipeline: CEO Conference Presentation Revealed - StockTitan
abrdn plc Has $2.69 Million Stake in TScan Therapeutics, Inc. (NASDAQ:TCRX) - MarketBeat
TScan Therapeutics: Finding Their Footing After An Eventful ASH Meeting (NASDAQ:TCRX) - Seeking Alpha
Finanzdaten der Tscan Therapeutics Inc-Aktie (TCRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Tscan Therapeutics Inc-Aktie (TCRX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Lynx1 Capital Management LP | 10% Owner |
Dec 12 '24 |
Buy |
3.01 |
31,800 |
95,629 |
5,257,347 |
| Lynx1 Capital Management LP | 10% Owner |
Nov 15 '24 |
Buy |
4.34 |
947 |
4,114 |
5,225,547 |
| Klencke Barbara | Director |
Sep 23 '24 |
Buy |
5.29 |
5,000 |
26,450 |
45,000 |
| Klencke Barbara | Director |
Aug 23 '24 |
Buy |
5.69 |
5,000 |
28,450 |
35,000 |
| Klencke Barbara | Director |
Aug 26 '24 |
Buy |
5.53 |
5,000 |
27,650 |
40,000 |
| ZDRAVESKI ZORAN | See Remarks |
Aug 23 '24 |
Option Exercise |
3.38 |
157,186 |
531,520 |
169,402 |
| ZDRAVESKI ZORAN | See Remarks |
Aug 23 '24 |
Sale |
5.78 |
164,686 |
952,116 |
4,716 |
3.01%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):